Basket | Login | Register


DESPIAD (coming soon)

Phase II trials

Scientific title

Depletion of Serum Amyloid P Component In Alzheimer’s Disease (DESPIAD). Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.

Study sponsor

University College London


Mild Alzheimer’s disease


Phase II

Name of drug

CPHPC (also called miridesap)

Link to full text

Please note that an accessible easy read version of this study is not yet available. The pharmaceutical company running this trial and a member of the European Working Group of People with Dementia are currently reviewing this document.



Last Updated: Thursday 07 February 2019


  • Acknowledgements

    Alzheimer Europe's Clinical Trial Watch received funding under an operating grant from the European Union’s Health Programme (2014–2020).
  • European Union